首页> 外文期刊>Circulation: An Official Journal of the American Heart Association >ANNEXA (TM)-R Part 2: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Sustained Reversal of Rivaroxaban-Induced Anticoagulation in Older Subjects by Andexanet Alfa (PRT064445), a Universal Antidote for Factor XA (FXA) Inhibitors
【24h】

ANNEXA (TM)-R Part 2: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Sustained Reversal of Rivaroxaban-Induced Anticoagulation in Older Subjects by Andexanet Alfa (PRT064445), a Universal Antidote for Factor XA (FXA) Inhibitors

机译:ANNEXA(TM)-R第2部分:3期随机,双盲,安慰剂对照试验,证明瑞伐沙班诱导的老年受试者抗凝的持续逆转由Andexanet Alfa(PRT064445)(一种XA因子抑制剂(FXA)的通用解毒剂)持续进行

获取原文
获取原文并翻译 | 示例
           

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号